A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

ABSTRACT: A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.

DISEASE(S): Squamous Cell Carcinoma Of Head And Neck,Cutaneous Melanoma,Uveal Melanoma,Melanoma,Non-small Cell Lung Cancer,Colorectal Cancer,Head And Neck Squamous Cell Carcinoma,Breast Cancer

PROVIDER: 2751104 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR